Bispecific T-cell engager (BiTE-format monoclonal antibody)

Class

Bispecific T-cell engager (BiTE-format monoclonal antibody)

Pathway

Redirects/activates T cells against tumor cells via CD3 engagement; the specific tumor-antigen arm is not publicly disclosed

Bispecific T-cell engagers, often described by the BiTE format, are engineered antibody constructs with two distinct binding arms fused into a single molecule. One arm binds CD3, a signaling component of the T-cell receptor complex present on nearly all T lymphocytes; the other arm binds an antigen displayed on the surface of tumor cells. By simultaneously engaging both, the molecule physically bridges a T cell to a cancer cell, forming a contact zone that mimics the immune synapse used in natural T-cell killing. This bridging activates the T cell independent of its normal antigen-recognition machinery, triggering release of cytotoxic proteins that destroy the attached tumor cell. The biological rationale is to redirect the immune system's own killing machinery toward malignant cells that might otherwise evade detection, particularly in cancers where tumor cells downregulate the signals normally needed for immune recognition. This mechanism has broad relevance across hematologic malignancies and solid tumors, wherever a tumor-restricted or tumor-enriched surface antigen can be identified as the second binding target. The overall strategy trades the specificity of the immune system's own recognition systems for engineered specificity, aiming to achieve potent, targeted cytotoxicity against cancer cells expressing the chosen antigen.